Passage Bio, Inc. ( (PASG) ) has released its Q2 earnings. Here is a breakdown of the information Passage Bio, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Passage Bio, Inc. is a clinical-stage genetic medicines company dedicated to developing therapies for neurodegenerative diseases, with a focus on innovative treatments targeting the underlying pathology of these conditions.
In its second-quarter 2025 earnings report, Passage Bio highlighted significant progress in its clinical trials and provided updates on its financial performance. The company completed the dosing of the second cohort in its upliFT-D study and reported encouraging interim data for its lead product candidate, PBFT02, which aims to treat frontotemporal dementia by elevating progranulin levels.
Key financial metrics for the quarter included a cash position of $57.6 million, with a cash runway extending into the first quarter of 2027. Research and development expenses decreased to $5.8 million from $10.4 million in the same period last year, and general and administrative expenses also saw a reduction. The company reported a net loss of $9.4 million, a significant improvement from the $16.0 million loss in the previous year.
Strategically, Passage Bio submitted an amended protocol for its upliFT-D study to global trial sites and health authorities, aiming to expand patient eligibility and improve trial outcomes. This amendment is expected to facilitate the enrollment of additional patient cohorts, further advancing the company’s clinical objectives.
Looking ahead, Passage Bio remains focused on executing its clinical development plans, with upcoming milestones including seeking regulatory feedback on its manufacturing process and trial design. The company is poised to continue its efforts in bringing innovative therapies to patients with neurodegenerative diseases.